MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
MannKind secured a grant from Breakthrough T1D to support the INHALE-1ST clinical study evaluating Afrezza in pediatric patients aged 10 to 18 with newly-diagnosed type 1 diabetes. The company has completed enrollment for the pilot phase of the trial, which assesses the safety and efficacy of inhaled insulin combined with daily basal insulin.
Key figures
- Patient age range
- 10 to <18 years
- Trial duration extension weeks
- 26
- Trial duration main phase weeks
- 13
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.